

# Publication of an insider information according to Art. 17 MAR



## CytoTools AG determines a cash capital increase under exclusion of subscription rights amounting to ten percent of the capital stock

**Darmstadt, 19<sup>th</sup> August 2020** - The Board of Directors of the CytoTools AG (ISIN DE000A0KFRJ1) has, with the approval of the Supervisory Board, decided to make a capital increase against cash contributions with the exclusion of existing shareholders' subscription rights, under partial utilization of the 2016 authorized capital.

In the course of the transaction, the capital stock of CytoTools AG is to be increased by nominal EUR 366,000.00 to EUR 4,028,000.00. The new shares will be taken over by a limited number of qualified investors within the framework of a private placement.

The placement price is EUR 10.00. The new shares are entitled to a share of the profits from 1<sup>st</sup> January 2020 and will be included in the existing listing in the subarea of the Open Market (Basic Board) of the German Stock Exchange in Frankfurt.

The proceeds from the transaction will finance the further growth of the CytoTools AG as well as the acquisition of further stakes in companies.

### Contact:

CytoTools AG  
Dr. Mark Andre Freyberg  
CEO  
Klappacher Str. 126  
D-64285 Darmstadt  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### About CytoTools:

CytoTools AG is a German biotechnology holding company which translates results from basic cell biological research on cell growth and programmed cell death into new forms of therapy for the causal treatment of disease and healing. CytoTools' versatile product pipeline includes self-developed chemical compounds and biopharmaceuticals which have the potential to offer new treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and investment company and as such has holdings in the subsidiaries DermaTools Biotech GmbH (62 %) and CytoPharma GmbH (50 %).

### Disclaimer

*This release contains certain forward-looking statements. These reflect the opinion of CytoTools at the date of this communication. The results actually achieved by CytoTools may differ considerably from the statements made in the future-oriented statements. CytoTools is not obliged to update future-oriented statements.*